JPS5549321A - Cellular toxin product formed by covalent bond of lysine a chain with antibody - Google Patents
Cellular toxin product formed by covalent bond of lysine a chain with antibodyInfo
- Publication number
- JPS5549321A JPS5549321A JP12525779A JP12525779A JPS5549321A JP S5549321 A JPS5549321 A JP S5549321A JP 12525779 A JP12525779 A JP 12525779A JP 12525779 A JP12525779 A JP 12525779A JP S5549321 A JPS5549321 A JP S5549321A
- Authority
- JP
- Japan
- Prior art keywords
- lysine
- antibody
- chain
- covalent bond
- product formed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
- C07K14/42—Lectins, e.g. concanavalin, phytohaemagglutinin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6819—Plant toxins
- A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
- A61K47/6827—Ricin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
- Y10S424/807—Monoclonal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
- Y10S530/864—Monoclonal
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7827838A FR2437213A1 (fr) | 1978-09-28 | 1978-09-28 | Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5549321A true JPS5549321A (en) | 1980-04-09 |
JPS6220999B2 JPS6220999B2 (ja) | 1987-05-11 |
Family
ID=9213144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP12525779A Granted JPS5549321A (en) | 1978-09-28 | 1979-09-28 | Cellular toxin product formed by covalent bond of lysine a chain with antibody |
Country Status (11)
Country | Link |
---|---|
US (1) | US4340535A (ja) |
JP (1) | JPS5549321A (ja) |
CA (1) | CA1188681A (ja) |
CH (1) | CH647411A5 (ja) |
DE (1) | DE2939165A1 (ja) |
ES (1) | ES484591A0 (ja) |
FR (1) | FR2437213A1 (ja) |
GB (1) | GB2034324B (ja) |
IT (1) | IT1207245B (ja) |
NL (1) | NL192088C (ja) |
SE (1) | SE446303B (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5748924A (en) * | 1980-07-14 | 1982-03-20 | Univ California | Antibody target cell injuring agent |
JPS58500482A (ja) * | 1981-04-06 | 1983-03-31 | フア−マシア・アクチエボラ−グ | 治療上活性な化合物およびそれを含有する薬学的組成物 |
JPS5874614A (ja) * | 1981-10-30 | 1983-05-06 | Teijin Ltd | 蛋白複合体及びその製造法 |
JPS58135821A (ja) * | 1981-11-20 | 1983-08-12 | サノフイ・ソシエテ・アノニム | リチンの鎖状部aと特異モノクロノ−ル抗体により構成される白血病t治療用抗癌剤 |
JPS6069033A (ja) * | 1983-06-21 | 1985-04-19 | ザ・ボ−ド・オブ・リ−ジエンツ・ザ・ユニバ−シテイ・オブ・テキサス・システム | 免疫毒素複合体 |
JPS62221700A (ja) * | 1984-09-25 | 1987-09-29 | ゾ−マ・コ−ポレ−シヨン | レクチン免疫毒素 |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4315851A (en) * | 1978-12-29 | 1982-02-16 | Kureha Kagaku Kogyo Kabushiki Kaisha | Pharmaceutical composition having antitumor activity |
US4440747A (en) * | 1980-09-30 | 1984-04-03 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibody-ricin hybrids as a treatment of murine graft-versus-host disease |
JPS57106626A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
JPS57106625A (en) * | 1980-12-22 | 1982-07-02 | Teijin Ltd | Cytotoxic protein complex and its preparation |
FI820020L (fi) * | 1981-01-12 | 1982-07-13 | Lilly Industries Ltd | Immunoglobulinkonjugater |
SE8102193L (sv) * | 1981-04-06 | 1982-10-07 | Pharmacia Ab | Terapeutiskt aktiv organisk forening och dess anvendning |
FR2504010B1 (fr) * | 1981-04-15 | 1985-10-25 | Sanofi Sa | Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation |
US5292668A (en) * | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US4444878A (en) * | 1981-12-21 | 1984-04-24 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
US5202252A (en) * | 1982-03-05 | 1993-04-13 | Houston Biotechnology Inc. | Monoclonal antibodies against lens epithelial cells and methods for preventing proliferation of remnant lens epithelial cells after extracapsular extraction |
FR2522968B1 (fr) * | 1982-03-10 | 1986-03-28 | Sanofi Sa | Medicament cytotoxique forme de l'association d'a u moins une immunotoxine et de la chloroquine |
FR2523445A1 (fr) * | 1982-03-17 | 1983-09-23 | Sanofi Sa | Nouveaux conjugues associant, par liaison covalente, une enzyme et un anticorps, et associations medicamenteuses utilisant lesdits conjugues |
WO1983004026A1 (fr) * | 1982-05-11 | 1983-11-24 | Genefusion S.A. | Agent cytotoxique |
US4468382A (en) * | 1982-07-15 | 1984-08-28 | New England Medical Center, Inc. | Polypeptide-toxin hybrid protein |
US4520226A (en) * | 1982-07-19 | 1985-05-28 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of graft versus host disease using a mixture of T-lymphocyte specific monoclonal antibody: ricin conjugates |
US4500637A (en) * | 1982-07-19 | 1985-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | Prevention of graft versus host disease following bone marrow transplantation |
US4485093A (en) * | 1982-08-13 | 1984-11-27 | Runge Richard G | Immunotoxin conjugate which comprises arsanilic acid, useful for treating malignant tumors, particularly pancreatic cancer |
JPS59116232A (ja) * | 1982-12-24 | 1984-07-05 | Teijin Ltd | 細胞毒性複合体及びその製造法 |
US4916213A (en) * | 1983-02-22 | 1990-04-10 | Xoma Corporation | Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof |
JPS59186924A (ja) * | 1983-04-08 | 1984-10-23 | Kureha Chem Ind Co Ltd | ヒト免疫グロブリン結合抗腫瘍剤 |
GB2142428A (en) * | 1983-06-23 | 1985-01-16 | Erba Farmitalia | Adenocarcinoma related antigenic determinants and antibodies specific thereto |
GB2148299B (en) * | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
US5169774A (en) * | 1984-02-08 | 1992-12-08 | Cetus Oncology Corporation | Monoclonal anti-human breast cancer antibodies |
DE3584486D1 (de) * | 1984-02-08 | 1991-11-28 | Cetus Corp | Toxinkonjugate. |
US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
US4894443A (en) * | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
CA1314245C (en) * | 1984-05-23 | 1993-03-09 | Franz Jansen | Process for the preparation of conjugates in which a monovalent carboxylic ionophore is associated by means of a covalent bond with a macromolecule, which are useful as immunotoxin potentiators |
US4670563A (en) * | 1984-06-20 | 1987-06-02 | Sanofi | Imidazolides as intermediates for the synthesis of cytotoxic conjugates |
FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
PT80662B (en) * | 1984-06-20 | 1986-12-09 | Sanofi Sa | Process to obtain anti-tumoral glycoprotein modified on its glycidic portions |
US6808901B1 (en) * | 1984-09-03 | 2004-10-26 | Celltech R&D Limited | Production of chimeric antibodies |
US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
US5185434A (en) * | 1985-02-13 | 1993-02-09 | Sanofi | Prolonged-action immunotoxins containing a glycopeptide constituent which inactivates ribosomes, modified on its polysaccharide units |
FR2577135B1 (fr) * | 1985-02-13 | 1989-12-15 | Sanofi Sa | Immunotoxines a longue duree d'action comportant un constituant glycopeptidique inactivant les ribosomes modifie sur ses motifs polysaccharidiques |
US4698420A (en) * | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
WO1986005098A1 (en) * | 1985-03-04 | 1986-09-12 | Dana-Farber Cancer Institute, Inc. | Immunotoxin and method of making |
US4888415A (en) * | 1985-03-04 | 1989-12-19 | Dana-Farber Cancer Institute, Inc. | Gelonin immunotoxin |
US4689311A (en) * | 1985-09-30 | 1987-08-25 | Rhode Island Hospital | Screening antibodies for capacity to deliver toxin to target cells |
US4731439A (en) * | 1985-11-22 | 1988-03-15 | Oncogen | Snake venom growth arresting peptide |
US4962188A (en) * | 1985-12-06 | 1990-10-09 | Cetus Corporation | Recombinant ricin toxin A chain conjugates |
US4911911A (en) * | 1985-12-20 | 1990-03-27 | Sanofi | Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff's base and in-vivo prolonged action immunotoxins containing such a glycoprotein |
IL80973A (en) * | 1985-12-20 | 1992-08-18 | Sanofi Sa | Modified ribosome-inactivating glycoproteins,their preparation,immunotoxins containing them and pharmaceutical compositions containing such immunotoxins |
EP0252951A4 (en) * | 1986-01-06 | 1988-09-07 | Univ Melbourne | TECHNETIUM-ANTIBODY CONJUGATES. |
US4689401A (en) * | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
US5242823A (en) * | 1986-03-07 | 1993-09-07 | International Genetic Engineering, Inc. | Cloning of the 38kd Mycoplasma hyorhinis regression-associated antigen |
US4748112A (en) * | 1986-03-07 | 1988-05-31 | International Genetic Engineering, Inc. | Methods and compositions relating to regression-associated antigens |
US4877868A (en) * | 1986-03-12 | 1989-10-31 | Neorx Corporation | Radionuclide antibody coupling |
WO1987005515A1 (en) * | 1986-03-20 | 1987-09-24 | Dana-Farber Cancer Institute, Inc. | Lectin complex and method and probe for making same |
US5239062A (en) * | 1986-03-20 | 1993-08-24 | Dana-Farber Cancer Institute, Inc. | Blocked lectins, methods and affinity support for making same using affinity ligands, and method of killing selected cell populations having reduced nonselective cytotoxicity |
US5395924A (en) * | 1986-03-20 | 1995-03-07 | Dana-Farber Cancer Institute, Inc. | Blocked lectins; methods and affinity support for making the same using affinity ligands; and method of killing selected cell populations having reduced non-selective cytotoxicity |
US4880935A (en) * | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
FR2601680B1 (fr) * | 1986-07-15 | 1990-06-29 | Sanofi Sa | Inhibiteur de la synthese proteique, procede d'isolement, utilisation et compositions pharmaceutiques en contenant |
US4771128A (en) * | 1986-10-10 | 1988-09-13 | Cetus Corporation | Method of purifying toxin conjugates using hydrophobic interaction chromatography |
US4871350A (en) * | 1986-11-04 | 1989-10-03 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
US5616122A (en) * | 1986-11-04 | 1997-04-01 | Baylor College Of Medicine | Methods and compositions for preventing secondary cataracts |
US5055291A (en) * | 1986-11-04 | 1991-10-08 | Baylor College Of Medicine | Compositions for preventing secondary cataracts |
US5158893A (en) * | 1986-12-11 | 1992-10-27 | Peralta Cancer Research Institute | Methods and compositions for screening carcinomas |
US5149528A (en) * | 1987-04-10 | 1992-09-22 | Zymogenetics, Inc. | Cytotoxic protein from Trichosanthes kirilowii |
US4985541A (en) * | 1987-04-10 | 1991-01-15 | Zymogenetics, Inc. | Novel cytotoxic protein |
US5591829A (en) * | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
US4865841A (en) * | 1987-10-23 | 1989-09-12 | Imre Corporation | Methods and compositions for transient elimination of humoral immune antibodies |
JPH0535249Y2 (ja) * | 1988-03-31 | 1993-09-07 | ||
WO1989012624A2 (en) * | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5241078A (en) * | 1988-06-14 | 1993-08-31 | Cetus Oncology | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5171563A (en) * | 1988-09-30 | 1992-12-15 | Neorx Corporation | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates |
US5162218A (en) * | 1988-11-18 | 1992-11-10 | The Regents Of The University Of California | Conjugated polypeptides and methods for their preparation |
WO1991010742A1 (en) * | 1990-01-16 | 1991-07-25 | Replgien Corporation | Monoclonal antibody specific for non-immunodominant epitope of hiv proteins |
US5191066A (en) * | 1990-12-07 | 1993-03-02 | Abbott Laboratories | Site-specific conjugation of immunoglobulins and detectable labels |
AU654563B2 (en) * | 1991-07-24 | 1994-11-10 | Imperial Chemical Industries Plc | Proteins |
US5578706A (en) * | 1993-11-04 | 1996-11-26 | Board Of Regents, The University Of Texas | Methods and compositions concerning homogenous immunotoxin preparations |
US5690935A (en) * | 1995-01-13 | 1997-11-25 | Regents Of The University Of Minnesota | Biotherapy of cancer by targeting TP-3/P80 |
US6146628A (en) * | 1995-07-11 | 2000-11-14 | Regents Of The University Of Minnesota And Rutgers | Biotherapeutic agents comprising recombinant PAP and PAP mutants |
ZA9711548B (en) * | 1996-12-24 | 1999-06-23 | Res Dev Foundation | Ricin inhibitors and methods for use thereof |
US6673914B1 (en) | 1998-01-22 | 2004-01-06 | John Wayne Cancer Institute | Human tumor-associated gene |
ES2533255T3 (es) | 1998-07-13 | 2015-04-08 | Board Of Regents, The University Of Texas System | Utilización de anticuerpos anti-aminofosfolípidos para el tratamiento del cáncer |
DE69934903T2 (de) * | 1998-11-10 | 2007-10-18 | Emory University | Mitogene regulatoren |
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
GB9926875D0 (en) * | 1999-11-12 | 2000-01-12 | Microbiological Research Agenc | Use of lytic toxins and toxin conjugates |
AU5003001A (en) | 2000-03-06 | 2001-09-17 | Univ Kentucky Res Found | Methods to impair hematologic cancer progenitor cells and compounds related thereto |
US8163289B2 (en) * | 2001-03-09 | 2012-04-24 | Iterative Therapeutics, Inc. | Methods and compositions involving polymeric immunoglobulin fusion proteins |
CA2437958C (en) | 2001-03-09 | 2018-10-30 | University Of Chicago | Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
WO2002079499A1 (en) | 2001-04-02 | 2002-10-10 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
US6846484B2 (en) | 2001-12-28 | 2005-01-25 | Regents Of The University Of Minnesota | DTAT fusion toxin |
US20050095627A1 (en) * | 2003-09-03 | 2005-05-05 | The Salk Institute For Biological Studies | Multiple antigen detection assays and reagents |
WO2007025166A2 (en) * | 2005-08-25 | 2007-03-01 | Repair Technologies, Inc. | Devices, compositions and methods for the protection and repair of cells and tissues |
FR2900341B1 (fr) | 2006-04-27 | 2012-09-14 | Centre Nat Rech Scient | Utilisation de ligands synthetiques multivalents de la nucleoline de surface pour le traitement du cancer |
US8163279B2 (en) | 2007-04-13 | 2012-04-24 | Stemline Therapeutics, Inc. | IL3Rα antibody conjugates and uses thereof |
MX2010005104A (es) | 2007-11-09 | 2010-08-04 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpo anti-factor de crecimiento endotelial vascular y metodos. |
WO2009141687A1 (en) * | 2008-05-22 | 2009-11-26 | Centre National De La Recherche Scientifique (Cnrs) | New optically pure compounds for improved therapeutic efficiency |
GB0909904D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Product |
GB0909906D0 (en) | 2009-06-09 | 2009-07-22 | Affitech As | Antibodies |
GB201002238D0 (en) | 2010-02-10 | 2010-03-31 | Affitech As | Antibodies |
CN103338782A (zh) | 2010-10-04 | 2013-10-02 | 国家科学研究中心 | 包含表面核仁素的多价合成配体和糖胺聚糖的组合物 |
GB201020738D0 (en) | 2010-12-07 | 2011-01-19 | Affitech Res As | Antibodies |
EP3613765A1 (en) | 2012-08-03 | 2020-02-26 | Dana-Farber Cancer Institute, Inc. | Antibody against repulsive guidance molecule b (rgmb) |
AU2014241442B2 (en) | 2013-03-14 | 2018-11-15 | Regeneron Pharmaceuticals, Inc. | Human antibodies to GREM 1 |
EP3293275B1 (en) | 2013-06-06 | 2021-08-04 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms |
EP3757130A1 (en) | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2016094273A1 (en) | 2014-12-08 | 2016-06-16 | Dana-Farber Cancer Institute, Inc. | Methods for upregulating immune responses using combinations of anti-rgmb and anti-pd-1 agents |
WO2017066561A2 (en) | 2015-10-16 | 2017-04-20 | President And Fellows Of Harvard College | Regulatory t cell pd-1 modulation for regulating t cell effector immune responses |
KR20190080825A (ko) | 2016-03-21 | 2019-07-08 | 다나-파버 캔서 인스티튜트 인크. | T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도 |
WO2018044640A1 (en) | 2016-08-29 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension |
TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素a毒素之人類抗體 |
WO2020251924A1 (en) | 2019-06-12 | 2020-12-17 | Regeneron Pharmaceuticals, Inc. | Human antibodies to bone morphogenetic protein 6 |
CN116964088A (zh) | 2021-01-25 | 2023-10-27 | 里珍纳龙药品有限公司 | 用于治疗肺动脉高压(pah)的抗pdgf-b抗体和使用方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2456224A1 (de) * | 1974-11-28 | 1976-08-12 | Karl Dr Med Theurer | Verwendung von nativen antikoerpern oder von antikoerper-fragmenten mit kovalent gebundenen oder konjugierten zytostatisch und/bzw. oder zytotoxisch wirkenden substanzen fuer die krebstherapie |
GB1541435A (en) * | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
GB1446536A (en) * | 1975-02-21 | 1976-08-18 | Yeda Res & Dev | Pharmaceutically active compositions |
IL47372A (en) * | 1975-05-27 | 1979-10-31 | Yeda Res & Dev | Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same |
-
1978
- 1978-09-28 FR FR7827838A patent/FR2437213A1/fr active Granted
-
1979
- 1979-09-26 SE SE7907994A patent/SE446303B/sv not_active IP Right Cessation
- 1979-09-26 CA CA000336385A patent/CA1188681A/en not_active Expired
- 1979-09-26 CH CH8644/79A patent/CH647411A5/fr not_active IP Right Cessation
- 1979-09-27 DE DE19792939165 patent/DE2939165A1/de active Granted
- 1979-09-27 US US06/079,441 patent/US4340535A/en not_active Expired - Lifetime
- 1979-09-28 GB GB7933670A patent/GB2034324B/en not_active Expired
- 1979-09-28 ES ES484591A patent/ES484591A0/es active Granted
- 1979-09-28 JP JP12525779A patent/JPS5549321A/ja active Granted
- 1979-09-28 IT IT7926118A patent/IT1207245B/it active
- 1979-09-28 NL NL7907251A patent/NL192088C/nl not_active IP Right Cessation
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5616418A (en) * | 1979-07-20 | 1981-02-17 | Teijin Ltd | Antitumor protein complex and its preparation |
JPS5748924A (en) * | 1980-07-14 | 1982-03-20 | Univ California | Antibody target cell injuring agent |
JPS58500482A (ja) * | 1981-04-06 | 1983-03-31 | フア−マシア・アクチエボラ−グ | 治療上活性な化合物およびそれを含有する薬学的組成物 |
JPS5874614A (ja) * | 1981-10-30 | 1983-05-06 | Teijin Ltd | 蛋白複合体及びその製造法 |
JPH0428719B2 (ja) * | 1981-10-30 | 1992-05-15 | Teijin Kk | |
JPS58135821A (ja) * | 1981-11-20 | 1983-08-12 | サノフイ・ソシエテ・アノニム | リチンの鎖状部aと特異モノクロノ−ル抗体により構成される白血病t治療用抗癌剤 |
JPS6069033A (ja) * | 1983-06-21 | 1985-04-19 | ザ・ボ−ド・オブ・リ−ジエンツ・ザ・ユニバ−シテイ・オブ・テキサス・システム | 免疫毒素複合体 |
JPS62221700A (ja) * | 1984-09-25 | 1987-09-29 | ゾ−マ・コ−ポレ−シヨン | レクチン免疫毒素 |
Also Published As
Publication number | Publication date |
---|---|
FR2437213A1 (fr) | 1980-04-25 |
GB2034324A (en) | 1980-06-04 |
JPS6220999B2 (ja) | 1987-05-11 |
NL7907251A (nl) | 1980-04-01 |
SE7907994L (sv) | 1980-03-29 |
IT7926118A0 (it) | 1979-09-28 |
CA1188681A (en) | 1985-06-11 |
US4340535A (en) | 1982-07-20 |
CH647411A5 (fr) | 1985-01-31 |
ES8101384A1 (es) | 1980-12-16 |
NL192088C (nl) | 1997-02-04 |
SE446303B (sv) | 1986-09-01 |
DE2939165A1 (de) | 1980-04-10 |
IT1207245B (it) | 1989-05-17 |
ES484591A0 (es) | 1980-12-16 |
FR2437213B1 (ja) | 1983-05-06 |
GB2034324B (en) | 1984-01-04 |
NL192088B (nl) | 1996-10-01 |
DE2939165C2 (ja) | 1989-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS5549321A (en) | Cellular toxin product formed by covalent bond of lysine a chain with antibody | |
AU529502B2 (en) | Conveyor belt | |
IT1049407B (it) | Nastro trasportatore a listelli snodati | |
CA1010407A (en) | Endless conveyor magnetic refuse separator | |
YU22176A (en) | Method of manufacturing articles of thermoplastics | |
AU528509B2 (en) | Applying belt fasteners to a belt | |
GB2037690B (en) | Chain conveyors | |
GB1550953A (en) | Endless belt conveyor | |
AU507997B2 (en) | Packing articles by pressing into base material | |
GB1553903A (en) | Endless conveyor | |
JPS5685287A (en) | Production of monoclonal antibody | |
AU512781B2 (en) | Conveyor belt manufacture | |
CA1020112A (en) | Conveyor belt drive assembly | |
JPS5589111A (en) | Conveyor chain | |
GB2035943B (en) | Belt conveyor having a curved path of travel | |
IT1059891B (it) | Trasportatore a catena per il trasporto di alberi o simili | |
GB2049597B (en) | Endless conveyor with containers carried by a pair of ropes | |
AU527121B2 (en) | Belt conveyor | |
JPS54119082A (en) | Modified asparagenase deactivated antibody property thereof and production | |
JPS52154519A (en) | Production of labeled antibody | |
JPS54149185A (en) | Carrying pallet automatic stop motion of chain conveyor | |
CA1018092A (en) | Endless chain conveyor link | |
AU474552B2 (en) | Improvements relating to endless band conveyors | |
IT1058835B (it) | Trasportatore a catena | |
IT1059454B (it) | Trasportatore a catena |